Biomoda Partners with Christiana Care to Complete Pilot Study on Cancer Diagnostic

In a press release this morning, Biomoda, Inc. (OTCBB: BMOD) announced that The Helen F. Graham Cancer Center associated with Christiana Care Health System, a screening site for the International Early Lung Cancer Program (I-ELCAP), will recruit a cohort of patients diagnosed with lung cancer to participate in the final stage of the Phase II pilot study of the investigational CyPath® assay, an early-stage diagnostic test for lung cancer.

According to Mr. John Cousins, President of Biomoda, “Running our diagnostic test on a control group of patients who are known to have lung cancer but have not yet started therapy will provide the final data we need to complete the pilot phase of our study.  Christiana Care is a national role model for both patient care and cancer research. We could not ask for a better partner.”

Read More

Biomoda Commends New Mexico Governor for Proclaiming National Lung Cancer Awareness Month

In a press release today, Biomoda, Inc. (OTCBB: BMOD) thanked New Mexico Governor Bill Richardson for joining the fight against lung cancer by proclaiming November as Lung Cancer Awareness Month throughout New Mexico.

“It’s particularly appropriate to acknowledge Gov. Richardson on Veterans Day because his administration and the New Mexico Legislature have been proactive and forward-thinking in their support for our landmark screening program to detect early-stage lung cancer in New Mexico veterans,” commented John Cousins, Biomoda’s President.  “We know that veterans have a 25 percent higher risk of lung cancer than the general population due to greater exposure to known carcinogens, such as Agent Orange and asbestos, and higher smoking rates.”

Read More

Biomoda Honors Veterans with Pledge to Lower Rate of Lung Cancer

In a press release this morning, John Cousins, President of Biomoda, Inc. (OTCBB: BMOD), called upon governors in all 50 states to proclaim November “Lung Cancer Awareness Month” on behalf of veterans and their families and pledged to continue the company’s focus on veterans in the research, development and commercialization of diagnostic technology for detection of early-stage lung cancer.

According to Cousins, “America can truly honor its 25 million veterans by making a commitment to fight lung cancer. Veterans have a 25 percent higher risk than the general population of developing lung cancer and dying from the disease.  The men and women who served our country deserve nationwide recognition that lung cancer is a significant threat to their health, and they deserve our commitment to lower their risk with early detection and awareness.”

Read More

Biomoda Awarded New Patent

ALBUQUERQUE, N.M.–(BUSINESS WIRE)–Biomoda, Inc. (OTCBB: BMOD), an Albuquerque-based cancer diagnostics company, announces that it has received notice of allowance for a U.S. Patent protecting the proprietary formula for the composition that binds to cancer cells which is utilized in Biomoda’s screening assay for the early detection of cancer.

The U.S. Patent entitled “Method for Making 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine (TCPP) Solution and Composition Comprising TCPP,” describes the new formulation of the Biomoda assay trademarked under the name CyPath®.

“This patent basically gives Biomoda a lock on the ‘recipe’ for the TCPP Labeling Solution,” said Biomoda President John Cousins. “Our formulation moves beyond the original work done on TCPP at Los Alamos National Laboratory and incorporates the cutting-edge science we are doing in our own lab.”

Read More

Biomoda Prepares for Phase III Clinical Trials

ALBUQUERQUE, N.M.–(BUSINESS WIRE)–Medical diagnostics company Biomoda, Inc. (OTCBB: BMOD – News) is taking preliminary steps to launch multisite Phase III clinical trials of its in-vitro diagnostic for early-stage lung cancer, trademarked under the name CyPath®.“As the Phase II trial wraps up, we are making sure that all the pieces are in place to move immediately to a nationwide Phase III,” Biomoda President John Cousins said. “Most significantly, Dr. Thomas Bauer, the Principal Investigator (PI) overseeing Phase II, has agreed to continue in the same role for our Phase III trials. Dr. Bauer is widely recognized as one of the top lung cancer researchers in the field, and we are privileged to be working with him.”

Bauer, chief of thoracic surgery at the Helen F. Graham Cancer Center, Christiana Care Health System, and head of Christiana’s participation in the International Early Lung Cancer Action Program (I-ELCAP), is coordinating site selection for the final phase of testing on the CyPath® assay. Bauer’s work with Biomoda follows the I-ELCAP Enrollment and Screening Protocol, and all sites selected for the Phase III trials will be I-ELCAP approved.

Biomoda Names New Corporate Secretary

In a press release this morning, Biomoda, Inc. (OTCBB: BMOD) announced that Maria Zannes will serve as the Company’s Corporate Secretary.  Zannes brings more than 30 years of experience in the environmental and energy industries where she worked in multiple capacities, including federal lobbyist and company president. Formerly president of a national waste-to-energy trade group in Washington, D.C., Zannes currently consults for private clients in the medical, energy, and environmental industries. She is a research associate for Columbia University’s Earth Engineering Center and a member of the Board of Directors of American Homecoming Foundation, a non-profit organization focused on providing assistance to homeless veterans. She was a legislative aide and press secretary to U.S. Rep. Charles Wilson (D-Texas). Zannes is licensed to practice law in Washington State and New Mexico.

Read More

Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study

ALBUQUERQUE, N.M., Oct. 23 /PRNewswire-FirstCall/ — Biomoda, Inc. (OTC Bulletin Board: BMOD – News), a diagnostics company focused on the development of accurate, inexpensive and noninvasive in-vitro tests for the early detection of cancer, has met its recruitment goal for New Mexico veterans with a history of heavy smoking required to complete the Phase II clinical trial of Biomoda’s early-stage diagnostic for lung cancer. The next stage of the Phase II trial calls for Biomoda to begin testing samples from already-diagnosed lung cancer patients in accordance with the study protocol approved by the U.S. Food and Drug Administration (FDA).

Read More

Biomoda, Inc. – An In-Depth 3-Part Series

Biomoda is developing a diagnostic tool to assist clinicians in early detection and staged diagnosis of lung cancer. Biomoda’s lead product is a combination of a chemical that attaches itself to the lung cancer and allows the lab workers to see it in a sputum sample with Biomoda’s proprietary Dark-Field Microscopy Platform.  The following is a more detailed, third-party analysis of the Company’s technology, the Company’s operations, and the Company’s opportunities.

Part I – Early Cancer Test, and when is it up for Approval?

Part II – How does this test work?

Part III – The Clinical Trials and Market Estimate

Biomoda Engages Renowned Researcher to Lead Longitudinal Component of Lung Cancer Study

In a news release out this morning, Biomoda, Inc. (OTCBB: BMOD) announced that they have engaged Dr. Thomas Bauer, a renowned researcher in the field of cancer diagnostics, to read the follow-up CT scans and other data on study participants as part of the longitudinal component of the research of the Company’s ongoing Phase II clinical trial for the early detection of lung cancer.

Dr. Bauer brings a wealth of experience to the Biomoda team with a long history in the medical/cancer diagnostic industry including posts as  chief of thoracic surgery at the Helen F. Graham Cancer Center, Christiana Care Health System, in Delaware as well as clinical assistant professor of surgery at Jefferson Medical College and adjunct assistant professor of biological sciences at the University of Delaware. Dr Bauer has led several lung and esophageal cancer studies and heads up Christiana’s participation in the International Early Lung Cancer Action Program (I-ELCAP).

Biomoda, Inc. has announced recently that the Company’s Phase II clinical trial, in which they have enrolled 500 military veterans for the early screening and detection of lung cancer is proceeding on schedule with over 130 participants screened to date. The Company’s core technology, is based on a group of patents held by the Company for a molecular biomarker called TCPP, which preferentially binds with cancer cells and fluoresces red under ultraviolet light. Biomoda’s screening protocal is non-invasive, cost effective and looks to be highly reliable in the diagnosis of lung cancer at an earlier stage that current screening protocals such as MRI and CT/PET scans, which could make it a highly valuable low cost, early screening tool for determining cancer in asymptomatic individuals.

To read today’s full press release click here

Biomoda Investor Presentation

Biomoda, Inc. (OTCBB: BMOD) traveled to San Diego, California to meet with investors in both one-on-one and group meetings.  There was tremendous interest for both types of meetings and our due diligence luncheon was standing room only with brokers, analysts, and fund managers, all of whom were excited about the Company, its management team, and its recent developments.  Click on the picture below to watch an excerpt from the lunch meeting.